Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase IIa, Multicentre, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Safety, Tolerability and Efficacy of Treatment With BI 655130 in Adult Patients With Moderate to Severe Atopic Dermatitis

Trial Profile

Phase IIa, Multicentre, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Safety, Tolerability and Efficacy of Treatment With BI 655130 in Adult Patients With Moderate to Severe Atopic Dermatitis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 01 Mar 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Spesolimab (Primary)
  • Indications Atopic dermatitis
  • Focus Therapeutic Use
  • Sponsors Boehringer Ingelheim

Most Recent Events

  • 27 Feb 2023 Primary endpoint has not been met, (Percentage change from baseline in the Eczema Area and Severity Index (EASI) Score at Week 16), as per Results published in the Journal of the European Academy of Dermatology and Venereology
  • 27 Feb 2023 Results published in the Journal of the European Academy of Dermatology and Venereology
  • 16 Sep 2020 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top